Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer Results From a Randomized Trial

被引:24
|
作者
Hoffman, Karen E. [1 ]
Skinner, Heath [1 ]
Pugh, Thomas J. [1 ]
Voong, Khinh R. [1 ]
Levy, Lawrence B. [1 ]
Choi, Seungtaek [1 ]
Frank, Steven J. [1 ]
Lee, Andrew K. [1 ]
Mahmood, Usama [1 ]
McGuire, Sean E. [1 ]
Schlembach, Pamela J. [1 ]
Du, Weiliang [1 ]
Johnson, Jennifer [1 ]
Kudchadker, Rajat J. [1 ]
Kuban, Deborah A. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, 1515 Holcombe Blvd,Unit 1202, Houston, TX 77030 USA
关键词
prostate cancer; radiation therapy; hypofractionation; patient-reported outcomes; QUALITY-OF-LIFE; EXTERNAL-BEAM RADIOTHERAPY; LATE TOXICITY; ALPHA/BETA; GY;
D O I
10.1097/COC.0000000000000325
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Hypofractionated prostate radiotherapy may increase biologically effective dose delivered while shortening treatment duration, but information on patient-reported urinary, bowel, and sexual function after dose-escalated hypofractionated radiotherapy is limited. We report patient-reported outcomes (PROs) from a randomized trial comparing hypofractionated and conventional prostate radiotherapy. Methods: Men with localized prostate cancer were enrolled in a trial that randomized men to either conventionally fractionated intensity-modulated radiation therapy (CIMRT, 75.6 Gy in 1.8 Gy fractions) or to dose-escalated hypofractionated IMRT (HIMRT, 72 Gy in 2. Gy fractions). Questionnaires assessing urinary, bowel, and sexual function were completed pretreatment and at 2, 3, 4, and 5 years after treatment. Results: Of 203 eligible patients, 185 were evaluable for PROs. A total of 173 completed the pretreatment questionnaire (82 CIMRT, 91 HIMRT) and 102 completed the 2-year questionnaire (46 CIMRT, 56 HIMRT). Patients who completed PROs were similar to those who did not complete PROs (all P>0.05). Patient characteristics, clinical characteristics, and baseline symptoms were well balanced between the treatment arms (all P>0.05). There was no difference in patient-reported bowel (urgency, control, frequency, or blood per rectum), urinary (dysuria, hematuria, nocturia, leakage), or sexual symptoms (erections firm enough for intercourse) between treatment arms at 2, 3, 4, and 5 years after treatment (all P>0.01). Concordance between physician-assessed toxicity and PROs varied across urinary and bowel domains. Discussion: We did not detect an increase in patient-reported urinary, bowel, and sexual symptom burden after dose-escalated intensity-modulated prostate radiation therapy using a moderate hypofractionation regimen (72 Gy in 2.4 Gy fractions) compared with conventionally fractionated radiation.
引用
收藏
页码:558 / 567
页数:10
相关论文
共 50 条
  • [1] Acute patient-reported toxicities after proton therapy or intensity-modulated radiotherapy for prostate cancer
    Gergelis, Kimberly
    Bai, Miao
    Whitaker, Thomas
    Routman, David M.
    Sir, Mustafa
    Choo, Richard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [2] Long-Term Patient-Reported Bowel and Urinary Quality of Life in Patients Treated with Intensity-Modulated Radiotherapy and Intensity-Modulated Proton Therapy for Localized Prostate Cancer
    Gergelis, K. R.
    Bai, M.
    Ma, J.
    Routman, D. M.
    Stish, B. J.
    Davis, B. J.
    Pisansky, T. M.
    Whitaker, T.
    Choo, C. R.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E385 - E385
  • [3] Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer
    Bahig, Houda
    Gunn, Brandon G.
    Garden, Adam S.
    Ye, Rong
    Hutcheson, Kate
    Rosenthal, David, I
    Phan, Jack
    Fuller, Clifton D.
    Morrison, William H.
    Reddy, Jay Paul
    Ng, Sweet Ping
    Gross, Neil D.
    Sturgis, Erich M.
    Ferrarotto, Renata
    Gillison, Maura
    Frank, Steven J.
    [J]. INTERNATIONAL JOURNAL OF PARTICLE THERAPY, 2021, 8 (01) : 213 - 222
  • [4] Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy
    Akthar, Adil S.
    Liao, Chuanhong
    Eggener, Scott E.
    Liauw, Stanley L.
    [J]. EUROPEAN UROLOGY, 2019, 76 (05) : 686 - 692
  • [5] A comparison of sexual function following radiotherapy for prostate cancer: Results of a prospective, randomized trial of hypofractionated intensity modulated radiotherapy
    Buyyounouski, M. K.
    Li, T.
    Watkins-Bruner, D.
    Horwitz, E. M.
    Pollack, A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S7 - S8
  • [6] Post Intensity-Modulated Radiation Therapy Urinary Function for Prostate Cancer; A Prospective Study
    Allameh, Farzad
    Karkan, Morteza Fallah
    Rahavian, Amir Hossein
    Mofid, Bahram
    Azghandi, Samira
    Abedi, Amir Reza
    Basiri, Abbas
    Montazeri, Saeed
    [J]. INTERNATIONAL JOURNAL OF CANCER MANAGEMENT, 2020, 13 (06) : 1 - 5
  • [7] Comparative Effectiveness Study of Patient-Reported Outcomes After Proton Therapy or Intensity-Modulated Radiotherapy for Prostate Cancer
    Hoppe, Bradford S.
    Michalski, Jeff M.
    Mendenhall, Nancy P.
    Morris, Christopher G.
    Henderson, Randal H.
    Nichols, Romaine C.
    Mendenhall, William M.
    Williams, Christopher R.
    Regan, Meredith M.
    Chipman, Jonathan J.
    Crociani, Catrina M.
    Sandler, Howard M.
    Sanda, Martin G.
    Hamstra, Daniel A.
    [J]. CANCER, 2014, 120 (07) : 1076 - 1082
  • [8] Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial
    Teixeira Leite, Elton Trigo
    Angotti Ramos, Clarissa Cerchi
    Bertotti Ribeiro, Victor Augusto
    Salvajoli, Bernardo Peres
    Nahas, William Carlos
    Salvajoli, Joao Victor
    Moraes, Fabio Ynoe
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 109 (05): : 1263 - 1270
  • [9] Patient Reported Quality of Life after Moderately Hypofractionated Proton Beam Therapy or Intensity Modulated Radiation Therapy for Prostate Cancer
    Lukez, A.
    Handorf, E.
    Shulman, R. M.
    Stish, B. J.
    Davis, B. J.
    Hallman, M. A.
    Horwitz, E. M.
    Vapiwala, N.
    Wong, J. K.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S91 - S92
  • [10] Patient-reported functional outcomes after hypofractionated radiation for prostate cancer
    NossiteR, J.
    Sujenthiran, A.
    Cowling, T.
    Parry, M.
    Charman, S.
    Cathcart, P.
    Clarke, N.
    Payne, H.
    Van der Meulen, J.
    Aggarwal, A.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S106 - S107